FPAS
SRPT icon

Focus Partners Advisor Solutions’s Sarepta Therapeutics SRPT Stock Holding History

Focus Partners Advisor Solutions’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$492K Sell
22,590
-5,881
-21% -$114K 0.01% 795
2025
Q4 		$613K Buy
28,471
+10,298
+57% +$217K 0.01% 652
2025
Q3 		$321K Buy
+18,173
New +$324K ﹤0.01% 882

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Focus Partners Advisor Solutions's SRPT Position: Q1 2026 in Review

Focus Partners Advisor Solutions reduced its Sarepta Therapeutics (SRPT) stake by 21% in Q1 2026, selling an estimated $114K and leaving 22,590 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #795.

Focus Partners Advisor Solutions first reported a position in SRPT in Q3 2025 and has held it in 3 quarters since. The position peaked at $613K in Q4 2025. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Focus Partners Advisor Solutions held 22,590 shares of Sarepta Therapeutics worth $492K as of Q1 2026.
  • Focus Partners Advisor Solutions sold 5,881 Sarepta Therapeutics shares in Q1 2026, an estimated $114K.
  • Sarepta Therapeutics made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #795 holding.
  • Focus Partners Advisor Solutions first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Focus Partners Advisor Solutions's Sarepta Therapeutics position peaked at $613K in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.